Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Eun Ji Park, Sung Mook Lim, Kang Choon Lee & Dong Hee Na. (2016) Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015). Expert Opinion on Therapeutic Patents 26:7, pages 833-842.
Read now
Read now
Irl B. Hirsch, Doron Schneider, Aaron King, William H. Polonsky, Timothy S. Reid, Jay Shubrook, Carol A. Verderese, Jeffrey Wallace & Matthew C. Riddle. (2014) A Short-Acting GLP-1 Analog or Prandial Insulin to Supplement Basal Insulin?—Moving Toward Personalized Management of Type 2 Diabetes Mellitus. Postgraduate Medicine 126:3, pages 135-144.
Read now
Read now
Malcolm A. Young, Jeffrey A. Wald, Jessica E. Matthews, Fred Yang & Rickey R. Reinhardt. (2014) Effect of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Albiglutide. Postgraduate Medicine 126:3, pages 35-46.
Read now
Read now
Tracy Setji & Mark Feinglos. (2013) Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 8:3, pages 229-238.
Read now
Read now
Alan J Garber. (2012) Novel GLP-1 receptor agonists for diabetes. Expert Opinion on Investigational Drugs 21:1, pages 45-57.
Read now
Read now
Asger Lund, Filip K Knop & Tina Vilsbøll. (2011) Emerging GLP-1 receptor agonists. Expert Opinion on Emerging Drugs 16:4, pages 607-618.
Read now
Read now
Articles from other publishers (40)
Maryam Ehsasatvatan & Bahram Baghban Kohnehrouz. (2023) Designing and computational analyzing of chimeric long-lasting GLP-1 receptor agonists for type 2 diabetes. Scientific Reports 13:1.
Crossref
Crossref
Matthias Tschöp, Ruben Nogueiras & Bo Ahrén. (2023) Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy. Diabetologia.
Crossref
Crossref
V. P. Martinovich & K. U. Baradzina. (2022) Peptide Hormones in Medicine: A 100-Year History. Russian Journal of Bioorganic Chemistry 48:2, pages 221-232.
Crossref
Crossref
Donald J. AbrahamMichael Wagner, Andreas Evers, Martin Bossart & Anish Konkar. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
69
.
Peng Huang, Lingzhang Meng, Junhua Tan, Xianjun Gu, Meiying Huang, Feifan Huang, Ruiying Ma & Jie Wang. (2021) S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors. Life Sciences 270, pages 119136.
Crossref
Crossref
Lars Linderoth, Jacob Kofoed, János T. Kodra, Steffen Reedtz‐Runge & Thomas Kruse. 2021. Successful Drug Discovery. Successful Drug Discovery
87
110
.
Parisa Yousefpour, Anastasia Varanko, Rishi Subrahmanyan & Ashutosh Chilkoti. (2020) Recombinant Fusion of Glucagon‐Like Peptide‐1 and an Albumin Binding Domain Provides Glycemic Control for a Week in Diabetic Mice. Advanced Therapeutics 3:10, pages 2000073.
Crossref
Crossref
Seyed Ebrahim Alavi, Peter J. Cabot & Peter M. Moyle. (2019) Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. Molecular Pharmaceutics 16:6, pages 2278-2295.
Crossref
Crossref
Lotte Bjerre Knudsen & Jesper Lau. (2019) The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology 10.
Crossref
Crossref
Roland Böttger, Daniel Knappe & Ralf Hoffmann. (2018) PEGylated prodrugs of antidiabetic peptides amylin and GLP-1. Journal of Controlled Release 292, pages 58-66.
Crossref
Crossref
Michaela Gebauer & Arne Skerra. (2018) Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action. Bioorganic & Medicinal Chemistry 26:10, pages 2882-2887.
Crossref
Crossref
Jing Han, Yiyun Wang, Qinghua Meng, Guangchao Li, Fangmin Huang, Su Wu, Yingying Fei, Feng Zhou & Junjie Fu. (2017) Design, synthesis and biological evaluation of PEGylated Xenopus glucagon-like peptide-1 derivatives as long-acting hypoglycemic agents. European Journal of Medicinal Chemistry 132, pages 81-89.
Crossref
Crossref
Sergei Pechenov, Himanshu Bhattacharjee, Daniel Yin, Sachin Mittal & J. Anand Subramony. (2017) Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery. Advanced Drug Delivery Reviews 112, pages 106-122.
Crossref
Crossref
Seungah LeeDong Yun Lee. (2017) Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Annals of Pediatric Endocrinology & Metabolism 22:1, pages 15.
Crossref
Crossref
Chris de Graaf, Dan Donnelly, Denise Wootten, Jesper Lau, Patrick M. Sexton, Laurence J. Miller, Jung-Mo Ahn, Jiayu Liao, Madeleine M. Fletcher, Dehua Yang, Alastair J. H. Brown, Caihong Zhou, Jiejie Deng & Ming-Wei Wang. (2016) Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes. Pharmacological Reviews 68:4, pages 954-1013.
Crossref
Crossref
A. L. João, F. Reis & R. Fernandes. (2016) The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond. Obesity Reviews 17:7, pages 553-572.
Crossref
Crossref
Arun K. Sharma, Punniyakoti V. Thanikachalam & Satyendra K. Rajput. (2016) Albiglutide: Is a better hope against diabetes mellitus?. Biomedicine & Pharmacotherapy 77, pages 120-128.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
419
458
.
A. Penfornis & J.-P. Sauvanet. (2014) Agonistes du récepteur du GLP-1 en une injection hebdomadaire : quelles perspectives pour le patient diabétique de type 2 ?. Médecine des Maladies Métaboliques 8:6, pages 612-622.
Crossref
Crossref
Agnieszka M Falinska, Tricia Tan & Stephen Bloom. (2014) Gut hormones and Type 2 diabetes mellitus. Diabetes Management 4:6, pages 501-513.
Crossref
Crossref
Vladimer Darsalia, David Nathanson, Thomas Nyström, Thomas Klein, Åke Sjöholm & Cesare Patrone. (2014) GLP-1R activation for the treatment of stroke: Updating and future perspectives. Reviews in Endocrine and Metabolic Disorders 15:3, pages 233-242.
Crossref
Crossref
Bo Ahrén, Susan L. Johnson, Murray Stewart, Deborah T. CirkelFred Yang, Caroline Perry & Mark N. Feinglos. (2014) HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin. Diabetes Care 37:8, pages 2141-2148.
Crossref
Crossref
Ralph A. DeFronzo, Curtis L. Triplitt, Muhammad Abdul-Ghani & Eugenio Cersosimo. (2014) Novel Agents for the Treatment of Type 2 Diabetes. Diabetes Spectrum 27:2, pages 100-112.
Crossref
Crossref
I. B. Hirsch, J. B. Buse, J. Leahy, J. B. McGill, A. Peters, H. W. Rodbard, R. R. Rubin, J. S. Skyler, C. A. Verderese & M. C. Riddle. (2014) Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, Obesity and Metabolism 16:3, pages 206-214.
Crossref
Crossref
Young Sil EomByung-Joon Kim. (2014) Glucagon-Like Peptide-1 (GLP-1) Agonist. Korean Journal of Medicine 87:1, pages 9.
Crossref
Crossref
Prashant Nadkarni, Oleg G. Chepurny & George G. Holz. 2014. Glucose Homeostatis and the Pathogenesis of Diabetes Mellitus. Glucose Homeostatis and the Pathogenesis of Diabetes Mellitus
23
65
.
Gábor Mezo. 2013. Amino Acids, Peptides and Proteins. Amino Acids, Peptides and Proteins
203
252
.
B. Guerci & J.-P. Sauvanet. (2013) Traitement du diabète de type 2 : l’exénatide, en alternative ou en association à l’insuline ?. Médecine des Maladies Métaboliques 7:5, pages 449-463.
Crossref
Crossref
Bo Ahrén. (2013) GLP-1 receptor agonists in the treatment of Type 2 diabetes. Diabetes Management 3:5, pages 401-413.
Crossref
Crossref
Martin Lorenz, Andreas Evers & Michael Wagner. (2013) Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorganic & Medicinal Chemistry Letters 23:14, pages 4011-4018.
Crossref
Crossref
Chichi Huang & Ronald V. Swanson. 2013. Fusion Protein Technologies for Biopharmaceuticals. Fusion Protein Technologies for Biopharmaceuticals
123
142
.
Young Min Cho, Catherine E. Merchant & Timothy J. Kieffer. (2012) Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacology & Therapeutics 135:3, pages 247-278.
Crossref
Crossref
Maria Tzefos, Kira Harris & Adriane Brackett. (2012) Clinical Efficacy and Safety of Once-Weekly Glucagon-Like Peptide-1 Agonists in Development for Treatment of Type 2 Diabetes Mellitus in Adults. Annals of Pharmacotherapy 46:1, pages 68-78.
Crossref
Crossref
Baptist Gallwitz. 2012. Appetite Control. Appetite Control
185
207
.
Daniel Rycroft & Lucy J. Holt. 2012. Single Domain Antibodies. Single Domain Antibodies
457
473
.
Hao Sun & Dennis O. Scott. (2011) Impact of genetic polymorphisms of cytochrome P450 2 C (CYP2C) enzymes on the drug metabolism and design of antidiabetics. Chemico-Biological Interactions 194:2-3, pages 159-167.
Crossref
Crossref
Evan M. Sisson. (2012) Liraglutide: Clinical Pharmacology and Considerations for Therapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31:9, pages 896-911.
Crossref
Crossref
Weike Bao, Karpagam Aravindhan, Hasan Alsaid, Thimmaiah Chendrimada, Matthew Szapacs, David R. Citerone, Mark R. Harpel, Robert N. Willette, John J. Lepore & Beat M. Jucker. (2011) Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency. PLoS ONE 6:8, pages e23570.
Crossref
Crossref
Chinmay S. Marathe, Christopher K. Rayner, Karen L. Jones & Michael Horowitz. (2011) Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function. Experimental Diabetes Research 2011, pages 1-10.
Crossref
Crossref
Byung-Joon Kim, Jie Zhou, Bronwen Martin, Olga D. Carlson, Stuart Maudsley, Nigel H. Greig, Mark P. Mattson, Ellen E. Ladenheim, Jay Wustner, Andrew Turner, Homayoun Sadeghi & Josephine M. Egan. (2010) Transferrin Fusion Technology: A Novel Approach to Prolonging Biological Half-Life of Insulinotropic Peptides. Journal of Pharmacology and Experimental Therapeutics 334:3, pages 682-692.
Crossref
Crossref